Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study

Overview of attention for article published in Frontiers in immunology, October 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 25 Dimensions

Readers on

mendeley: 25 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 32,797 followers.

New Research: Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study: As treatment options in advanced systematic lupus erythematosus (SLE) are limited,… https://t.co/

01 Oct 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.